Published in Exp Neurol on September 01, 2003
Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates. ACS Chem Neurosci (2011) 0.82
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet (2011) 5.01
Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect (2011) 3.87
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Solvent exposures and Parkinson disease risk in twins. Ann Neurol (2011) 2.92
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis (2002) 2.83
Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci (2007) 2.28
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem (2001) 1.99
Head injury and Parkinson's disease risk in twins. Ann Neurol (2006) 1.93
Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem (2010) 1.82
Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci (2003) 1.80
Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci (2003) 1.77
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology (2009) 1.63
Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem (2005) 1.59
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol (2002) 1.51
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis (2006) 1.43
Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol (2002) 1.39
MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One (2008) 1.39
SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS One (2011) 1.37
Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry (2003) 1.33
Redox cycling of the herbicide paraquat in microglial cultures. Brain Res Mol Brain Res (2005) 1.27
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol (2007) 1.25
Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp Neurol (2007) 1.24
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol (2002) 1.22
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol (2004) 1.20
Crossroads in GDNF therapy for Parkinson's disease. Mov Disord (2006) 1.19
Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol (2008) 1.18
Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging (2006) 1.18
Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol (2012) 1.14
Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J (2004) 1.13
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem (2010) 1.11
Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis (2007) 1.11
Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother (2009) 1.08
Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One (2010) 1.08
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem (2006) 1.06
Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem (2006) 1.06
Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology (2010) 1.06
Voluntarily simulated tremor in normal subjects. Neurophysiol Clin (2002) 1.03
Can cellular models revolutionize drug discovery in Parkinson's disease? Biochim Biophys Acta (2009) 1.03
Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med (2013) 1.02
Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol (2008) 1.01
Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis (2005) 1.00
Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem (2003) 1.00
Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J Neurosci (2006) 1.00
Paraquat neurotoxicity is mediated by a Bak-dependent mechanism. J Biol Chem (2007) 1.00
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease. Toxicol Lett (2011) 0.99
Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. J Neurochem (2006) 0.99
Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplication. J Parkinsons Dis (2011) 0.98
Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. Parkinsonism Relat Disord (2012) 0.98
The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods (2005) 0.96
Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage. Stem Cells Int (2012) 0.95
Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol (2006) 0.95
Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. J Neurochem (2007) 0.94
Stem cells for Parkinson disease and ALS: replacement or protection? Nat Med (2004) 0.93
Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem (2013) 0.93
Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord (2012) 0.91
Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox Res (2007) 0.90
Toxicity of redox cycling pesticides in primary mesencephalic cultures. Antioxid Redox Signal (2005) 0.90
Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim Biophys Acta (2009) 0.90
Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord (2011) 0.89
Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One (2013) 0.88
α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis (2012) 0.88
Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther (2004) 0.87
Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem (2002) 0.87
Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp Neurol (2009) 0.87
Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. J Parkinsons Dis (2011) 0.86
Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp Neurol (2006) 0.86
Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord (2005) 0.86
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol (2007) 0.86
The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys. Mov Disord (2002) 0.85
α-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. Mol Neurobiol (2012) 0.84
Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathol Commun (2015) 0.84
Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications. Curr Protein Pept Sci (2009) 0.84
Relationship of neighboring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease. Am J Neurodegener Dis (2012) 0.83
Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration. J Neurosci (2006) 0.83
Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine. J Pharmacol Exp Ther (2006) 0.83
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp Neurol (2007) 0.81
Letter regarding: "Paraquat: the red herring of Parkinson's disease research". Toxicol Sci (2007) 0.80
Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum. J Pharmacol Exp Ther (2008) 0.80
Parkin gene variations and parkinsonism: association does not imply causation. Ann Neurol (2007) 0.80
L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice. Neurotoxicology (2002) 0.79
Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. Mov Disord (2003) 0.79
The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. J Neurosurg (2009) 0.79
How many pathways are there to nigral death? Ann Neurol (2004) 0.78
GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol (2006) 0.78
Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage. J Mol Neurosci (2009) 0.77
Screening of ferritin light polypeptide 460-461InsA mutation in Parkinson's disease patients in North America. Neurosci Lett (2002) 0.76
Ubiquitin-positive neuronal and tau 2-positive glial inclusions in frontotemporal dementia of motor neuron type. Acta Neuropathol (2002) 0.76
Evidence of oxidative stress in young and aged DJ-1-deficient mice. FEBS Lett (2013) 0.76